Table Info

Treatment	Stage	Success rate
GTR	At diagnosis, symptomatic lesions	91%, 5-year survival rate [45]
STR/Biopsy	At diagnosis, symptomatic lesions	89%, 5-year survival rate [45]
Whole brain radiation therapy	At diagnosis	38.8%, 1-year survival [50]
SRS (overall)	At diagnosis	46.4%, 1-year survival [50]
SRS (HB)	At diagnosis	100%, 1-year survival [51]

Declarations

Author Contributions

CS and MEM: Conceptualization, Writing—original draft, Writing—review & editing, Project administration. M McNulty, ER, MW, DTC, M Micunovic, JR, and JP: Writing—original draft, Writing—review & editing. BLW: Supervision, Conceptualization, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Jejurkar MA, Lagad SG, Ranjan R. Recurrence of sporadic intracranial cerebellar hemangioblastoma: case report and literature review. Neurol India. 2021;69:508–10. [DOI] [PubMed]

Schattner A, Cagnano E, Dubin I. Cerebellar hemangioblastoma. Am J Med. 2018;131:e15–6. [DOI] [PubMed]

Roach J, Livermore L, Plaha P. Endoscope-assisted resection for cystic cerebellar hemangioblastomas. World Neurosurg. 2022;167:e217–21. [DOI] [PubMed]

Jeon C, Choi JW, Kong DS, Nam DH, Lee JI, Seol HJ. Treatment strategy for giant solid hemangioblastomas in the posterior fossa: a retrospective review of 13 consecutive cases. World Neurosurg. 2022;158:e214–24. [DOI] [PubMed]

Ren H, Wang Y, Ma Y, Huang Y. Microsurgical management of cerebellar hemangioblastoma via the suboccipital keyhole approach. Asian J Surg. 2022;45:2876–7. [DOI] [PubMed]

Amano T, Tokunaga S, Shono T, Mizoguchi M, Matsumoto K, Yoshida F, et al. Cerebellar hemangioblastoma manifesting as hearing disturbance. Neurol Med Chir (Tokyo). 2009;49:418–20. [DOI] [PubMed]

Wiley HE, Krivosic V, Gaudric A, Gorin MB, Shields C, Shields J, et al. Management of retinal hemangioblastoma in von Hippel-Lindau disease. Retina. 2019;39:2254–63. [DOI] [PubMed] [PMC]

Kumari N, Das S, Bhaduri A, Gandhi A. Retinal hemangioblastoma with extraocular extension: report of three cases. Ocul Oncol Pathol. 2021;7:177–81. [DOI] [PubMed] [PMC]

Yin X, Duan H, Yi Z, Li C, Lu R, Li L. Incidence, prognostic factors and survival for hemangioblastoma of the central nervous system: analysis based on the surveillance, epidemiology, and end results database. Front Oncol. 2020;10:570103. [DOI] [PubMed] [PMC]

10.

van der Horst-Schrivers ANA, Sluiter WJ, Kruizinga RC, van Leeuwaarde RS, Giles R, Olderode-Berends MJW, et al. The incidence of consecutive manifestations in Von Hippel-Lindau disease. Fam Cancer. 2019;18:369–76. [DOI] [PubMed] [PMC]

11.

Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of brain and other CNS tumors. Curr Neurol Neurosci Rep. 2021;21:68. [DOI] [PubMed] [PMC]

12.

Watanabe T, Suematsu Y, Saito K, Takeishi G, Yamashita S, Ohta H, et al. Selection of surgical approach for cerebellar hemangioblastomas based on venous drainage patterns. Neurosurg Rev. 2021;44:3567–79. [DOI] [PubMed]

13.

Riklin C, Seystahl K, Hofer S, Happold C, Winterhalder R, Weller M. Antiangiogenic treatment for multiple CNS hemangioblastomas. Onkologie. 2012;35:443–5. [DOI] [PubMed]

14.

Louise M Binderup M, Smerdel M, Borgwadt L, Beck Nielsen SS, Madsen MG, Møller HU, et al. Von Hippel-Lindau disease: updated guideline for diagnosis and surveillance. Eur J Med Genet. 2022;65:104538. [DOI] [PubMed]

15.

Klingler JH, Gläsker S, Bausch B, Urbach H, Krauss T, Jilg CA, et al. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Childs Nerv Syst. 2020;36:2537–52. [DOI] [PubMed] [PMC]

16.

Shively SB, Edwards NA, MacDonald TJ, Johnson KR, Diaz-Rodriguez NM, Merrill MJ, et al. Developmentally arrested basket/stellate cells in postnatal human brain as potential tumor cells of origin for cerebellar hemangioblastoma in von Hippel-Lindau patients. J Neuropathol Exp Neurol. 2022;81:885–99. [DOI] [PubMed] [PMC]

17.

Comelli I, Lippi G, Campana V, Servadei F, Cervellin G. Clinical presentation and epidemiology of brain tumors firstly diagnosed in adults in the Emergency Department: a 10-year, single center retrospective study. Ann Transl Med. 2017;5:269. [DOI] [PubMed] [PMC]

18.

Jankovic D, Vuong K, Splavski B, Rotim K, Arnautovic KI. Supratentorial hemangioblastoma in adults: a systematic review and comparison of infratentorial and spinal cord locations. World Neurosurg. 2023;173:48–62. [DOI] [PubMed]

19.

Ma D, Wang Y, Du G, Zhou L. Neurosurgical management of brainstem hemangioblastomas: a single-institution experience with 116 patients. World Neurosurg. 2015;84:1030–8. [DOI] [PubMed]

20.

Bamps S, Calenbergh FV, Vleeschouwer SD, Loon JV, Sciot R, Legius E, et al. What the neurosurgeon should know about hemangioblastoma, both sporadic and in Von Hippel-Lindau disease: a literature review. Surg Neurol Int. 2013;4:145. [DOI] [PubMed] [PMC]

21.

Park DM, Zhuang Z, Chen L, Szerlip N, Maric I, Li J, et al. Von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med. 2007;4:e60. [DOI] [PubMed] [PMC]

22.

Hemangioblastoma - about the disease [Internet]. [Cited 2023 Aug 17]. Available from: https://rarediseases.info.nih.gov/diseases/8232/hemangioblastoma

23.

Streitberger KJ, Lilaj L, Schrank F, Braun J, Hoffmann KT, Reiss-Zimmermann M, et al. How tissue fluidity influences brain tumor progression. Proc Natl Acad Sci U S A. 2020;117:128–34. [DOI] [PubMed] [PMC]

24.

Graner MW, Cumming RI, Bigner DD. The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. J Neurosci. 2007;27:11214–27. [DOI] [PubMed] [PMC]

25.

Soloukey S, Verhoef L, Generowicz BS, De Zeeuw CI, Koekkoek SKE, Vincent AJPE, et al. Case report: high-resolution, intra-operative µDoppler-imaging of spinal cord hemangioblastoma. Front Surg. 2023;10:1153605. [DOI] [PubMed] [PMC]

26.

Salceda S, Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 1997;272:22642–7. [DOI] [PubMed]

27.

Kim H, Shim BY, Lee SJ, Lee JY, Lee HJ, Kim IH. Loss of von Hippel-Lindau (VHL) tumor suppressor gene function: VHL-HIF pathway and advances in treatments for metastatic renal cell carcinoma (RCC). Int J Mol Sci. 2021;22:9795. [DOI] [PubMed] [PMC]

28.

Huntoon K, Wu T, Elder JB, Butman JA, Chew EY, Linehan WM, et al. Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease. J Neurosurg. 2016;124:971–6. [DOI] [PubMed] [PMC]

29.

Gläsker S, Vortmeyer AO, Lonser RR, Lubensky IA, Okamoto H, Xia JB, et al. Proteomic analysis of hemangioblastoma cyst fluid. Cancer Biol Ther. 2006;5:549–53. [DOI] [PubMed]

30.

Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1460–9. [DOI] [PubMed] [PMC]

31.

Bonosi L, Marrone S, Benigno UE, Buscemi F, Musso S, Porzio M, et al. Maximal safe resection in glioblastoma surgery: a systematic review of advanced intraoperative image-guided techniques. Brain Sci. 2023;13:216. [DOI] [PubMed] [PMC]

32.

Baig Mirza A, Gebreyohanes A, Knight J, Bartram J, Vastani A, Kalaitzoglou D, et al. Prognostic factors for surgically managed intramedullary spinal cord tumours: a single-centre case series. Acta Neurochir (Wien). 2022;164:2605–22. [DOI] [PubMed]

33.

Naik A, Smith EJ, Barreau A, Nyaeme M, Cramer SW, Najafali D, et al. Comparison of fluorescein sodium, 5-ALA, and intraoperative MRI for resection of high-grade gliomas: a systematic review and network meta-analysis. J Clin Neurosci. 2022;98:240–7. [DOI] [PubMed]

34.

Nikova AS, Vlotinou P, Karelis L, Karanikas M, Birbilis TA. Gross total resection with fluorescence could lead to improved overall survival rates: a systematic review and meta-analysis. Br J Neurosurg. 2022;36:316–22. [DOI] [PubMed]

35.

Mattogno PP, Menna G, Pennisi G, Corbi L, Sturiale CL, Polli FM, et al. Comparison of effectiveness, feasibility, indications, and limitations of different intraoperative dyes in spinal neuro-oncologic surgery. A systematic review. World Neurosurg. 2022;168:146–53. [DOI] [PubMed]

36.

Shimada K, Yamamoto Y, Miyamoto T, Sogabe S, Fujihara T, Nakajima K, et al. Efficacy of intra-arterial indocyanine green videoangiography in hemangioblastoma surgery: a case report. NMC Case Rep J. 2021;8:295–300. [DOI] [PubMed] [PMC]

37.

Yin X, Li C, Li L, Duan H. Safety and efficacy of surgical treatment for brainstem hemangioblastoma: a meta-analysis. Neurosurg Rev. 2021;44:799–806. [DOI] [PubMed] [PMC]

38.

Daly ME, Choi CY, Gibbs IC, Adler JR Jr, Chang SD, Lieberson RE, et al. Tolerance of the spinal cord to stereotactic radiosurgery: insights from hemangioblastomas. Int J Radiat Oncol Biol Phys. 2011;80:213–20. [DOI] [PubMed]

39.

Bridges KJ, Jaboin JJ, Kubicky CD, Than KD. Stereotactic radiosurgery versus surgical resection for spinal hemangioblastoma: a systematic review. Clin Neurol Neurosurg. 2017;154:59–66. [DOI] [PubMed]

40.

Graham CA, Cloughesy TF. Brain tumor treatment: chemotherapy and other new developments. Semin Oncol Nurs. 2004;20:260–72. [PubMed]

41.

Tashima T. Brain cancer chemotherapy through a delivery system across the blood-brain barrier into the brain based on receptor-mediated transcytosis using monoclonal antibody conjugates. Biomedicines. 2022;10:1597. [DOI] [PubMed] [PMC]

42.

Daneman R, Prat A. The blood–brain barrier. Cold Spring Harb Perspect Biol. 2015;7:a020412. [DOI] [PubMed] [PMC]

43.

Lampson LA. Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. MAbs. 2011;3:153–60. [DOI] [PubMed] [PMC]

44.

Do J, Foster D, Renier C, Vogel H, Rosenblum S, Doyle TC, et al. Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models. Breast Cancer Res Treat. 2014;144:93–101. [DOI] [PubMed] [PMC]

45.

Huang Y, Chan L, Bai HX, Li X, Zhang Z, Wang Y, et al. Assessment of care pattern and outcome in hemangioblastoma. Sci Rep. 2018;8:11144. [DOI] [PubMed] [PMC]

46.

Pierscianek D, Wolf S, Keyvani K, El Hindy N, Stein KP, Sandalcioglu IE, et al. Study of angiogenic signaling pathways in hemangioblastoma. Neuropathology. 2017;37:3–11. [DOI] [PubMed]

47.

Jin N, Sun C, Hua Y, Wu X, Li W, Yin Y. Anlotinib for the treatment of multiple recurrent lumbar and sacral cord hemangioblastomas: a case report. Front Oncol. 2022;12:859157. [DOI] [PubMed] [PMC]

48.

Migliorini D, Haller S, Merkler D, Pugliesi-Rinaldi A, Koka A, Schaller K, et al. Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review. CNS Oncol. 2015;4:387–92. [DOI] [PubMed] [PMC]

49.

Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al.; MK-6482-004 Investigators. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385:2036–46. [DOI] [PubMed] [PMC]

50.

Park K, Bae GH, Kim WK, Yoo CJ, Park CW, Kim SK, et al. Radiotherapy for brain metastasis and long-term survival. Sci Rep. 2021;11:8046. [DOI] [PubMed] [PMC]

51.

Kano H, Niranjan A, Mongia S, Kondziolka D, Flickinger JC, Lunsford LD. The role of stereotactic radiosurgery for intracranial hemangioblastomas. Neurosurgery. 2008;63:443–50. [DOI] [PubMed]

52.

Seyedmirzaei H, Shobeiri P, Turgut M, Hanaei S, Rezaei N. VEGF levels in patients with glioma: a systematic review and meta-analysis. Rev Neurosci. 2020;32:191–202. [DOI] [PubMed]

53.

Wilke C, Grosshans D, Duman J, Brown P, Li J. Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults. Neuro Oncol. 2018;20:597–607. [DOI] [PubMed] [PMC]

54.

Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9:193–9. [DOI] [PubMed] [PMC]

55.

Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–8. [DOI] [PubMed] [PMC]

56.

Sneed PK, Larson DA, Wara WM. Radiotherapy for cerebral metastases. Neurosurg Clin N Am. 1996;7:505–15. [PubMed]

57.

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500. [DOI] [PubMed]

58.

Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, et al. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys. 1980;6:1–9. [DOI] [PubMed]

59.

Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316:401–9. Erratum in: JAMA. 2018;320:510. [DOI] [PubMed] [PMC]

60.

Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol. 2017;13:52–64. [DOI] [PubMed] [PMC]

61.

Kazda T, Pospíšil P, Doleželová H, Jančálek R, Slampa P. Whole brain radiotherapy: consequences for personalized medicine. Rep Pract Oncol Radiother. 2013;18:133–8. [DOI] [PubMed] [PMC]

62.

Fetcko K, Lukas RV, Watson GA, Zhang L, Dey M. Survival and complications of stereotactic radiosurgery: a systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas. Medicine (Baltimore). 2017;96:e8293. [DOI] [PubMed] [PMC]

63.

Puataweepong P, Dhanachai M, Hansasuta A, Dangprasert S, Sitathanee C, Puddhikarant P, et al. The clinical outcome of intracranial hemangioblastomas treated with linac-based stereotactic radiosurgery and radiotherapy. J Radiat Res. 2014;55:761–8. [DOI] [PubMed] [PMC]

64.

Dalbah S, Bechrakis NE, Thomasen H, Flühs D, Rating P, Guberina M, et al. Brachytherapy for peripheral retinal capillary haemangioblastoma in von Hippel-Lindau disease. Klin Monbl Augenheilkd. 2021;238:781–7. English, German. [DOI] [PubMed]

65.

Kreusel KM, Bornfeld N, Lommatzsch A, Wessing A, Foerster MH, Kreusel KM. Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma. Ophthalmology. 1998;105:1386–92. [DOI] [PubMed]

66.

Chitti B, Goyal S, Sherman JH, Caputy A, Sarfaraz M, Cifter G, et al. The role of brachytherapy in the management of brain metastases: a systematic review. J Contemp Brachytherapy. 2020;12:67–83. [DOI] [PubMed] [PMC]

67.

Ferreira C, Sterling D, Reynolds M, Dusenbery K, Chen C, Alaei P. First clinical implementation of GammaTile permanent brain implants after FDA clearance. Brachytherapy. 2021;20:673–85. [DOI] [PubMed]

68.

Gessler DJ, Neil EC, Shah R, Levine J, Shanks J, Wilke C, et al. GammaTile® brachytherapy in the treatment of recurrent glioblastomas. Neurooncol Adv. 2021;4:vdab185. [DOI] [PubMed] [PMC]

69.

Odia Y, Gutierrez AN, Kotecha R. Surgically targeted radiation therapy (STaRT) trials for brain neoplasms: a comprehensive review. Neuro Oncol. 2022;24:S16–24. Erratum in: Neuro Oncol. 2023;25:423. [DOI] [PubMed] [PMC]

70.

Sarin H, Kanevsky AS, Wu H, Brimacombe KR, Fung SH, Sousa AA, et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med. 2008;6:80. [DOI] [PubMed] [PMC]

71.

Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv. 2009;6:1017–32. [DOI] [PubMed] [PMC]

72.

Wesolowski JR, Rajdev P, Mukherji SK. Temozolomide (Temodar). AJNR Am J Neuroradiol. 2010;31:1383–4. [DOI] [PubMed] [PMC]

73.

Kim BY, Jonasch E, McCutcheon IE. Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report. Target Oncol. 2012;7:145–9. [DOI] [PubMed] [PMC]

74.

Sizdahkhani S, Feldman MJ, Piazza MG, Ksendzovsky A, Edwards NA, Ray-Chaudhury A, et al. Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target. Sci Rep. 2017;7:40822. [DOI] [PubMed]

75.

Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist. 2010;15:819–25. [DOI] [PubMed] [PMC]

76.

Omar AI. Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report. J Med Case Rep. 2012;6:238. [DOI] [PubMed] [PMC]

77.

Mak G, Algird A, Greenspoon J, Provias J, Hirte H. Cervicomedullary hemangioblastoma treated with bevacizumab. Neurooncol Adv. 2020;2:vdaa076. [DOI] [PubMed] [PMC]

78.

Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol. 2018;36:867–74. [DOI] [PubMed] [PMC]

79.

Cuesta AM, Albiñana V, Gallardo-Vara E, Recio-Poveda L, de Rojas-P I, de Las Heras KVG, et al. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. Sci Rep. 2019;9:10062. [DOI] [PubMed] [PMC]

80.

Khan M, Lin J, Liao G, Li R, Wang B, Xie G, et al. Comparison of WBRT alone, SRS alone, and their combination in the treatment of one or more brain metastases: review and meta-analysis. Tumour Biol. 2017;39:1010428317702903. [DOI] [PubMed]

81.

Sokol Z, Hoeft A, Kung D, Belman N, Oselkin M. Intra-arterial bevacizumab for posterior fossa hemangioblastoma. Cureus. 2022;14:e32624. [DOI] [PubMed] [PMC]

82.

Paul M. Powerful chemotherapy drug reaches brain tumors using novel ultrasound technology [Internet]. Evanston: Northwestern University; c2023 [cited 2023 Nov 18]. Available from: https://news.northwestern.edu/stories/2023/05/chemotherapy-drug-reaches-brain-in-humans-for-first-time

83.

Tiny implanted devices give insights for treating brain tumors [Internet]. [Cited 2023 Nov 18]. Available from: https://www.nih.gov/news-events/nih-research-matters/tiny-implanted-devices-give-insights-treating-brain-tumors